Pharmasset (VRUS) Shares Higher Following Results of PSI-7977 Trial; Analyst Weighs In

Get Alerts VRUS Hot Sheet
Price: $0.00 --0%
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 30 | New: 20
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 30 | New: 20
Join SI Premium – FREE
Shares of Pharmasset (Nasdaq: VRUS) are up more than 8 percent in pre-market action Monday morning following better-than-expected results of its PSI-7977 drug for hepatitis C over the weekend.
Potentially moving on the news: shares on Inhibitex (Nasdaq: INHX) up 15.5 percent, shares of Vertex (Nasdaq: VRTX) down 4.5 percent.
An analyst at Brean Murray Carret said, "VRUS impressed a packed house of AASLD attendees by showing a 100% SVR rate in genotype 2/3 patients receiving PSI-7977 and ribavirin but no interferon. We believe this validates the company's decision to move into Phase 3 program with this combination and supports a new front line standard of care in these patients. Given the substantially better safety profile, we believe it will be unethical to use interferon in untreated Gt. 2/3 patients once PSI-7977 is approved."
For more ratings news on Pharmasset click here and for the rating history of Pharmasset click here.
Potentially moving on the news: shares on Inhibitex (Nasdaq: INHX) up 15.5 percent, shares of Vertex (Nasdaq: VRTX) down 4.5 percent.
An analyst at Brean Murray Carret said, "VRUS impressed a packed house of AASLD attendees by showing a 100% SVR rate in genotype 2/3 patients receiving PSI-7977 and ribavirin but no interferon. We believe this validates the company's decision to move into Phase 3 program with this combination and supports a new front line standard of care in these patients. Given the substantially better safety profile, we believe it will be unethical to use interferon in untreated Gt. 2/3 patients once PSI-7977 is approved."
For more ratings news on Pharmasset click here and for the rating history of Pharmasset click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Helmerich & Payne (HP) PT Lowered to $25 at CFRA, Double Downgrades to Sell
- Mettler-Toledo (MTD) PT Raised to $1,200 at Jefferies
- Post Holdings (POST) PT Raised to $131 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Corporate News, Momentum MoversRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!